Company Overview
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 80.9%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +12.60% |
| 6 Months: | - |
| 3 Months: | +39.62% |
| 1 Month: | +22.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)59.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 80.9%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPTX Seaport Therapeutics, Inc. | 22.34 | -13.62 | $1.20B | 0.00% | -36.95% | 80.91% | - | - |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 0 | - | 0 | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 16.18M | - | 27.54M | - |
| Operating Income | -16.18M | -18.47M | -27.54M | -65.81M |
| EBITDA | -15.87M | - | -27.19M | - |
| Interest Expense | - | - | - | - |
| Pretax Income | -13.09M | - | -24.89M | - |
| Tax Provision | 31.00K | - | 519.00K | - |
| Net Income | -13.12M | -15.08M | -25.41M | -62.60M |
| Diluted EPS | -0.34 | -6.40 | -0.48 | -1.78 |
| R&D Expense | 10.53M | 13.41M | 21.43M | 24.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 52.42M | 87.29M |
| Operating Income | -52.42M | -87.29M |
| EBITDA | -52.20M | -85.89M |
| Interest Expense | - | - |
| Pretax Income | -46.88M | -74.11M |
| Tax Provision | 0 | 773.00K |
| Net Income | -46.88M | -74.88M |
| Diluted EPS | -1.21 | -1.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 315.78M | 249.01M |
| Current Assets | 310.15M | 223.23M |
| Cash & Equivalents | 309.10M | 46.04M |
| Inventory | - | - |
| Receivables | 0 | 3.03M |
| Total Liabilities | 340.63M | 341.55M |
| Current Liabilities | 11.15M | 12.78M |
| Long Term Debt | - | - |
| Total Debt | 5.01M | 5.08M |
| Total Equity | -24.85M | -92.55M |
| Shares Outstanding | 53.03M | 53.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -29.63M | -77.94M |
| Investing Cash Flow | -113.00K | -184.25M |
| Financing Cash Flow | 339.30M | -873.00K |
| Capital Expenditure | -113.00K | -356.00K |
| Free Cash Flow | -29.74M | -78.30M |
| Net Change in Cash | 309.55M | -263.06M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 188.7% | 80.9% |
| ROCE % | -17.2% | -37.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Aberdeen Group plc | 0.58% | 310.36K | $6.41M |
| 2 | Alps Advisors Inc. | 0.10% | 54.33K | $1.12M |
| 3 | Assetmark, Inc. | - | 1.43K | $29.55K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPTX
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOZ0VOQWl4SnI0S1BhUlUyWi1wS3ltVGlMNjc1SjJQTFpWX01NZnVhOGZVN2pfeUw5YlM4X29JWlpPd1U5Y2RaWmFmVzRZeGVFNXZGRG5VOExYV21LVGk2eHZod0VzSUtDQVdDNVBDN2pybVRGUTQzYUZIbEJPZ2NBbg?oc=5" target="_…
Seaport Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPTX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8zUHhRMUxXRjZ5c0lUU3JtRWt2eF8wb2R5WHdwdlllZUdEdGc5SS1JaWpYWDZKM3pVbWNGWGJMNHVWM19GSUpfNmw3SllNQkZFelFfV2xJbm9VNVp6OXVLUzVBVUp2RHJCZS1rVVY3QkJKMGgxRzlr?oc=5" target="_blank">Seaport…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE81ZVdma2hyMUdWZ0FBNjBKamJOM1pvY1p6LTBqbURqWUU4bS1QcEp5UFNKMThPc3hvNVRkOUtVcVhkLXFuTk9kLUU4Q2tVZzNv?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQZjlDRGd0TVV3bVhzYjlFUzJQcnNFWDMzU2txRDhEb1hKMkVLNlFKUWV4Mkc4d2wyeHB1WXZhc1MxTTlhc3NncjJyVmJ0czMtR09TSnlpd25MVXBfODRzNzVtZ1pPZFVZS2R0X1ZER1NfajlHN1NaS2NFY2FBbnFhVUx5NWwyTDlZQ2RBWG…
Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX - Moomoo
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOWnU3b0JYUlZOaWswOG5rQXE0b3pKZG9Idmc1cV84TWx0akloSGxjTmxjTzZWMGtobDBsZ2d5cFdJRVVnV3pqSTVWWXFTY2lhT2dLbmIwVzl2YjNvZkdydEdpRE1ROEJNRGtpQWtIbTcwNFczck1EaWY4NWdsRGhRM3Mya0Y3OVZzc25XUl…
Earnings Flash (SPTX) Seaport Therapeutics Posts Q2 Loss $1.78 a Share - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPcEkyTk9KTGkyQl80cVJXV1RRaXFycC1IaUF0WjFBcmdvQVdOZ21yVlAzeUFCck5rSmtFSUZFb0hYdV9pSEZyU0xRRkoyZjhWSHV4aUJYT3FEdzVnNjhGaVd2TXE3Vk5WSF9qbWJtOEY4emxvZjctVnNyZTU4YWN6Ri1ZVFRVU2taWHlqRE…
SPTX — Frequently Asked Questions
What is the current share price of Seaport Therapeutics, Inc. (SPTX)?
As of 2026-08-05 17:25 PDT, Seaport Therapeutics, Inc. (SPTX) trades at $22.34 on NasdaqGS. Its 52-week range is $15.25 to $22.52.
What is the market capitalisation of SPTX?
Seaport Therapeutics, Inc. (SPTX) has a market capitalisation of $1.20B on NasdaqGS.
What is the P/E ratio of SPTX?
SPTX trades at a trailing price-to-earnings (P/E) ratio of -13.62. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is -0.46.
What is the return on equity (ROE) of SPTX?
SPTX has a return on equity (ROE) of 80.91%. Its return on capital employed (ROCE) is -36.95%.
Is SPTX a good stock to buy?
This page provides a data-driven analysis of Seaport Therapeutics, Inc. (SPTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.